NASDAQ$AKYA
Akoya Biosciences Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Akoya reported record revenue driven by increased reagents and services revenue and improved gross margin due to product mix and product business margin improvements.
Akoya Biosciences reported Q4 2023 revenue of $26.5 million, a 25.0% increase compared to the prior year period. The company's gross margin was 62.7%, and the operating loss decreased by 46.6% to $9.4 million. Cash and cash equivalents totaled $83.1 million.
- Revenue increased by 25.0% to $26.5 million compared to the prior year period, driven by higher reagents and services revenue.
- Gross margin improved to 62.7% due to product mix and improved margin on the product business.
- Operating loss decreased by 46.6% to $9.4 million due to operating leverage and efficiencies.
- Cash and cash equivalents totaled $83.1 million as of December 31, 2023.
Headline financials
Revenue & EPS history
Akoya · Revenue · Quarterly
$26.5M
Revenue by segment
Akoya · $18M total across 1 segment · Q3 2023
- Product revenue$18M+25.3%100.0%
Forward guidance
Akoya expects full year 2024 revenue guidance range of $114.0-118.0 million and projects operating cash flow breakeven by year end.
Tailwinds
- Anticipates strong topline growth in 2024.
- Projects operating cash flow breakeven by year end.
- Expanded installed base to nearly 1,200 instruments.
- Improved platform speeds.
- Simplified workflows with new offerings of reagents and analysis tools.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q4 2023
-3.7%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-17.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+13.7%
Q4 2021
Best reaction
-31.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | — | — | — | |
| Q1 2025 | +1.0% | +24.8% | +23.8% | |
| Q4 2025 | +3.8% | +9.2% | -30.7% | |
| Q3 2024 | -24.9% | -33.2% | -29.5% | |
| Q2 2024 | -9.5% | -0.9% | +5.5% | |
| Q1 2024 | -31.9% | -35.1% | -50.0% | |
| Q4 2023 | -15.4% | -17.1% | -28.1% | |
| Q3 2023 | +10.0% | +6.9% | +16.4% | |
| Q2 2023 | +0.9% | -6.5% | -23.9% | |
| Q1 2023 | -2.5% | -17.1% | -18.8% | |
| Q4 2022 | -7.3% | -17.2% | -36.6% | |
| Q3 2022 | -15.1% | — | — | |
| Q2 2022 | +5.0% | — | — | |
| Q1 2022 | -11.9% | — | — | |
| Q4 2021 | +13.7% | — | — | |
| Q3 2020 | +1.5% | — | — | |
| Q3 2021 | +0.2% | — | — | |
| Q2 2021 | -0.1% | — | — | |
| Q4 2020 | +9.5% | — | — | |
| Q1 2021 | +2.3% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro